BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

...European company that included contributions from Asian investors, in this case ORI Healthcare Fund and Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Aug 5, 2020
Finance

Data Bytes: led by ex-U.S. biopharmas, July follow-ons bring in $5.8B

...is collaborating with Eli Lilly and Co. (NYSE:LLY) to develop a mAb therapy for COVID-19. Shenzhen Hepalink Pharmaceutical...
...to raise twice the follow-on capital of 2019. Elizabeth S. Eaton, Staff Writer Shanghai Junshi Biosciences Co. Ltd. Shenzhen Hepalink Pharmaceutical...
BioCentury | Jul 10, 2020
Finance

Trio of Hong Kong listings raise $865M

...begin trading on the Hong Kong stock exchange this week, posted a modest first-day dip. Shenzhen Hepalink Pharmaceutical...
...hypertension and has 14 other candidates in development for ophthalmic disease in China. Hongjiang Li, Staff Writer Shenzhen Hepalink Pharmaceutical...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...kidney disease (CKD) caused by Alport syndrome Phase III data 2H19 Resverlogix Corp. (TSX:RVX) / Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Tel Aviv:RDHL; NASDAQ:RDHL) Talicia (RHB-105) Helicobacter pylori infection Submit NDA 1H19 Resverlogix Corp. (TSX:RVX) / Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Aug 17, 2018
Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

...mAb against S. aureus alpha-hemolysin (aHL) generated using MablgX technology. In February, Aridis partnered with Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...SIX:NOVN) AVXS-101 Spinal muscular atrophy (SMA) type 1 Submit BLA 2H18 Resverlogix Corp. (TSX:RVX) / Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | May 18, 2018
Finance

China comes to Europe

...two years. In November 2016, the firm co-led Kymab’s $100 million series C round alongside Shenzhen Hepalink Pharmaceutical Co. Ltd....
...plc (NASDAQ:NBRV), Dublin, Ireland Orchard Therapeutics Ltd., London, U.K. Oxford Nanopore Technologies Ltd., Oxford, U.K. Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Apr 3, 2018
Company News

Management tracks: Abeona, Dermavant, Assembly

...chief business development officer. He was chief strategic officer at the Hepalink USA subsidiary of Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Mar 9, 2018
Company News

Aridis, Shenzhen Hepalink form China JV

...Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals...
...Jose, Calif. Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399), Shenzhen, China Business: Infectious Alicia Parker Aerumab, panobacumab (AR-101, kbpa101) Salvecin (AR-301, kbsa301) Aridis Pharmaceuticals Inc. Shenzhen Hepalink Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 34
BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

...European company that included contributions from Asian investors, in this case ORI Healthcare Fund and Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Aug 5, 2020
Finance

Data Bytes: led by ex-U.S. biopharmas, July follow-ons bring in $5.8B

...is collaborating with Eli Lilly and Co. (NYSE:LLY) to develop a mAb therapy for COVID-19. Shenzhen Hepalink Pharmaceutical...
...to raise twice the follow-on capital of 2019. Elizabeth S. Eaton, Staff Writer Shanghai Junshi Biosciences Co. Ltd. Shenzhen Hepalink Pharmaceutical...
BioCentury | Jul 10, 2020
Finance

Trio of Hong Kong listings raise $865M

...begin trading on the Hong Kong stock exchange this week, posted a modest first-day dip. Shenzhen Hepalink Pharmaceutical...
...hypertension and has 14 other candidates in development for ophthalmic disease in China. Hongjiang Li, Staff Writer Shenzhen Hepalink Pharmaceutical...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...kidney disease (CKD) caused by Alport syndrome Phase III data 2H19 Resverlogix Corp. (TSX:RVX) / Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Tel Aviv:RDHL; NASDAQ:RDHL) Talicia (RHB-105) Helicobacter pylori infection Submit NDA 1H19 Resverlogix Corp. (TSX:RVX) / Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Aug 17, 2018
Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

...mAb against S. aureus alpha-hemolysin (aHL) generated using MablgX technology. In February, Aridis partnered with Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...SIX:NOVN) AVXS-101 Spinal muscular atrophy (SMA) type 1 Submit BLA 2H18 Resverlogix Corp. (TSX:RVX) / Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | May 18, 2018
Finance

China comes to Europe

...two years. In November 2016, the firm co-led Kymab’s $100 million series C round alongside Shenzhen Hepalink Pharmaceutical Co. Ltd....
...plc (NASDAQ:NBRV), Dublin, Ireland Orchard Therapeutics Ltd., London, U.K. Oxford Nanopore Technologies Ltd., Oxford, U.K. Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Apr 3, 2018
Company News

Management tracks: Abeona, Dermavant, Assembly

...chief business development officer. He was chief strategic officer at the Hepalink USA subsidiary of Shenzhen Hepalink Pharmaceutical Co. Ltd....
BioCentury | Mar 9, 2018
Company News

Aridis, Shenzhen Hepalink form China JV

...Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals...
...Jose, Calif. Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399), Shenzhen, China Business: Infectious Alicia Parker Aerumab, panobacumab (AR-101, kbpa101) Salvecin (AR-301, kbsa301) Aridis Pharmaceuticals Inc. Shenzhen Hepalink Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 34